☆ 3.8 Article

Barriers to patient access of CAR T cell therapies in Austria

MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Medicine, General & Internal

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

F. L. Locke et al.

Summary: This international phase 3 trial showed that axicabtagene ciloleucel therapy significantly improved event-free survival and response in patients with early relapsed or refractory large B-cell lymphoma compared to standard care, despite the expected high-grade toxic effects.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Medicine, General & Internal

Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma

Herve Tilly et al.

Summary: In untreated intermediate-risk or high-risk DLBCL patients, those who received pola-R-CHP had a lower risk of disease progression, relapse, or death compared to those who received R-CHOP. Overall survival and safety profiles were similar between the two groups.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Oncology

Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)

P. J. Hayden et al.

Summary: Several autologous chimeric antigen receptor T-cell (CAR-T) products targeting CD19 have been approved in Europe, with more approvals for different diseases expected in the near future. The European Society for Blood and Marrow Transplantation (EBMT)-Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association collaborated to provide best practice recommendations to support consistent and high-quality care in this rapidly advancing field.

ANNALS OF ONCOLOGY (2022)

Add to Collection

Article Hematology

GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany

Wolfgang A. Bethge et al.

Summary: A study conducted in Germany suggests that important outcome determinants of CD19-directed CAR T-cell treatment of LBCL in the real-world setting include bridging success, CAR-T product selection, LDH levels, and the absence of prolonged neutropenia and/or severe neurotoxicity.

BLOOD (2022)

Add to Collection

Letter Biophysics

Safety and feasibility of outpatient chimeric antigen receptor (CAR) T-cell therapy: experience from a tertiary care center

Azra Borogovac et al.

BONE MARROW TRANSPLANTATION (2022)

Add to Collection

Article Hematology

A national service for delivering CD19 CAR-Tin large B-cell lymphoma - The UK real-world experience

Andrea Kuhnl et al.

Summary: This study presents the results of a large national cohort of patients with relapsed/refractory large B-cell lymphoma (LBCL) treated with CD19 CAR-T therapy in the UK. The findings demonstrate the long-term efficacy of CAR-T treatment in LBCL patients, while emphasizing the significance of early treatment failure.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

Add to Collection

Article Oncology

Epidemiology of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in the United States and Western Europe: population-level projections for 2020-2025

Gena Kanas et al.

Summary: The study combined country-specific cancer registry data for the US and Western Europe with physician survey results to project an increase in the number of DLBCL and FL patients between 2020 and 2025. The research found that a majority of eligible DLBCL and FL patients initiated treatment in both the US and Western Europe. Further investigation is needed to understand why some eligible patients do not initiate treatment and to explore potential differences between countries.

LEUKEMIA & LYMPHOMA (2022)

Add to Collection

Letter Hematology

Feasibility of outpatient administration of axicabtagene ciloleucel and brexucabtagene autoleucel using telemedicine tools: The Vanderbilt experience

Bhagirathbhai Dholaria et al.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

Add to Collection

Review Pharmacology & Pharmacy

CAR T-Cell Therapies in Italy: Patient Access Barriers and Recommendations for Health System Solutions

Claudio Jommi et al.

Summary: CAR-T cell therapy has not been widely accessible for patients in Italy, and patient access barriers need to be addressed at the health system level to improve the situation.

FRONTIERS IN PHARMACOLOGY (2022)

Add to Collection

Article Immunology

Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO/GETH Spanish Groups

Mariana Bastos-Oreiro et al.

Summary: This study compared the efficacy of CAR-T cell therapy with the previous standard of care for refractory large B-cell lymphoma. The results showed that CAR-T therapy had superior efficacy in terms of progression-free survival and overall survival compared to the standard of care. Among the CAR-T cohort, axi-cel showed longer progression-free survival and overall survival than tisa-cel. However, axi-cel was also associated with a higher risk of severe cytokine release syndrome and neurotoxicity.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Article Hematology

Real-World Eligibility for Second-Line Chimeric Antigen Receptor T Cell Therapy in Large B Cell Lymphoma: A Population-Based Analysis

Robert Puckrin et al.

Summary: The ZUMA-7 trial showed the superiority of second-line CAR-T cell therapy over standard care chemotherapy for r/r LBCL. Our study found that many patients in the real-world setting were eligible for second-line CAR-T cell therapy. Compared to the current standard treatment, second-line CAR-T cell therapy could significantly increase the proportion of r/r LBCL patients receiving curative-intent treatment.

TRANSPLANTATION AND CELLULAR THERAPY (2022)

Add to Collection

Review Oncology

Side-effect management of chimeric antigen receptor (CAR) T-cell therapy

M-L Schubert et al.

Summary: CAR T-cell therapy targeting CD19-expressing B cells has shown promising results in treating refractory and/or relapsed B-cell malignancies, but also presents challenges such as cytokine release syndrome and neurotoxicity syndrome. Optimal management strategies for the side-effects associated with CAR T-cell therapy are crucial as it expands into other diseases in hematology and oncology.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Meeting Abstract Hematology

A Propensity Score-Matched Comparison of Axi-Cel and Tisa-Cel for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Real-Life: A Lysa Study from the Descar-T Registry

Emmanuel Bachy et al.

BLOOD (2021)

Add to Collection

Meeting Abstract Hematology

Real-World Outcomes of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Large B-Cell Lymphoma (LBCL): Impact of Age and Specific Organ Dysfunction

Frederick L. Locke et al.

BLOOD (2021)

Add to Collection

Article Oncology

Relapsed/refractory diffuse large B-cell lymphoma patients. A multicenter retrospective analysis of eligibility criteria for car-T cell therapy

Alice Di Rocco et al.

Summary: This study found that only 46.7% of DLBCL patients are eligible for CAR-T therapy, with eligible patients having longer overall survival. Advanced stage and poor ECOG score are significant prognostic factors for survival, and only 5.8% of DLBCL patients truly meet the eligibility criteria for CAR-T therapy.

LEUKEMIA & LYMPHOMA (2021)

Add to Collection

Editorial Material Hematology

COUNTERPOINT BiTEs better than CAR T cells

Marion Subklewe

BLOOD ADVANCES (2021)

Add to Collection

Article Biophysics

Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years

Jakob R. Passweg et al.

Summary: The number of Hematopoietic Cell Transplantations in Europe and collaborating countries has been on the rise, with a total of 48,512 HCT reported in 43,581 patients during 2019. The main indications were myeloid malignancies, lymphoid malignancies, and nonmalignant disorders. CAR-T cellular therapies also showed significant growth from 2017 to 2019. Over the past 30 years, there has been a substantial increase in the number of centers and countries performing HCT procedures, with more than 800,000 transplants reported overall.

BONE MARROW TRANSPLANTATION (2021)

Add to Collection

Review Oncology

Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia

G. Doug Myers et al.

Summary: CAR-T cell therapy is highly effective for refractory B-cell hematological malignancies, with high response rates and durable remissions in patients who have failed multiple lines of therapy. Although there is growing interest in delivering CAR-T cell therapy in the outpatient setting, it has not yet been adopted as standard clinical practice.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection

Review Biochemistry & Molecular Biology

CAR T-Cell Therapy in Hematological Malignancies

Theresa Haslauer et al.

Summary: CAR T-cells are a promising therapeutic approach for hematological malignancies, particularly in lymphoma and acute lymphocytic leukemia. Despite encouraging clinical results, challenges remain in treating other hematological malignancies.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Meeting Abstract Oncology

Outpatient practice pattern and remote patient monitoring for axicabtagene ciloleucel CAR-T therapy in patients with aggressive lymphoma.

Radhika Bansal et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Meeting Abstract Oncology

Real-world evidence of axicabtagene ciloleucel (Axi-cel) for the treatment of large B-cell lymphoma (LBCL) in the United States (US).

Caron A. Jacobson et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Hematology

CAR T-cell therapy for secondary CNS DLBCL

Gulrayz Ahmed et al.

Summary: The management of SCNS involvement in relapsed or refractory aggressive B-cell lymphomas remains challenging. However, CAR T-cell therapy combined with WBRT as a bridging therapy has shown promising outcomes in achieving complete response with manageable ICANS in some patients.

BLOOD ADVANCES (2021)

Add to Collection

Article Public, Environmental & Occupational Health

Real world data to identify target population for new CAR-T therapies

Valeria Belleudi et al.

Summary: By analyzing real world data, a precise identification of the target population for DLBCL patients suitable for CAR-T therapy has been achieved, highlighting the importance of this new treatment in clinical practice.

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2021)

Add to Collection

Article Hematology

Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)

Ibrahim Yakoub-Agha et al.

HAEMATOLOGICA (2020)

Add to Collection

Review Biotechnology & Applied Microbiology

'Off-the-shelf' allogeneic CAR T cells: development and challenges

S. Depil et al.

NATURE REVIEWS DRUG DISCOVERY (2020)

Add to Collection

Article Oncology

Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium

Loretta J. Nastoupil et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Oncology

Outpatient treatment with lisocabtagene maraleucel (liso-cel) across a variety of clinical sites from three ongoing clinical studies in relapsed/refractory (R/R) large B-cell lymphoma (LBCL).

Carlos R. Bachier et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Oncology

Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity

Caron A. Jacobson et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Hematology

CAR T cells or allogeneic transplantation as standard of care for advanced large B-cell lymphoma: an intent-to-treat comparison

Peter Dreger et al.

BLOOD ADVANCES (2020)

Add to Collection

Article Oncology

Ensuring center quality, proper patient selection and fair access to chimeric antigen receptor T-cell therapy: position statement of the Austrian CAR-T Cell Network

Hildegard T. Greinix et al.

MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY (2020)

Add to Collection

Article Hematology

Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma

Matthew J. Frigault et al.

BLOOD (2019)

Add to Collection

Article Hematology

CYTOKINE RELEASE SYNDROME AND NEUROTOXICITY BY BASELINE TUMOR BURDEN IN ADULTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH TISAGENLECLEUCEL

R.T. Maziarz et al.

HEMATOLOGICAL ONCOLOGY (2019)

Add to Collection

Article Oncology

Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma

John K. Lin et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection

Meeting Abstract Hematology

Clinical and Radiological Correlates of Neurotoxicity after Standard of Care Axicabtagene Ciloleucel in Patients with Relapsed/Refractory Large B-Cell Lymphoma

Paolo Strati et al.

BLOOD (2019)

Add to Collection

Meeting Abstract Hematology

Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium

N. Nora Bennani et al.

BLOOD (2019)

Add to Collection

Article Medicine, General & Internal

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Stephen J. Schuster et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Oncology

Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials

M. J. Maurer et al.

ANNALS OF ONCOLOGY (2018)

Add to Collection

Meeting Abstract Oncology

Outcomes by prior lines of therapy (LoT) in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B cell lymphoma.

Frederick Lundry Locke et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

Add to Collection

Article Hematology

Chimeric Antigen Receptor-T Cell Therapy Practical Considerations for Implementation in Europe

Jochen Buechner et al.

HEMASPHERE (2018)

Add to Collection

Letter Medicine, General & Internal

Anti-CD19 CAR T Cells in CNS Diffuse Large-B-Cell Lymphoma

Jeremy S. Abramson et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Medicine, General & Internal

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

S. S. Neelapu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Hematology

Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study

Michael Crump et al.

BLOOD (2017)

Add to Collection

Article Oncology

Lymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the UK's Haematological Malignancy Research Network

A. Smith et al.

BRITISH JOURNAL OF CANCER (2015)

Add to Collection

Article Hematology

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

Bertrand Coiffier et al.

BLOOD (2010)

Add to Collection

© Peeref 2019-2024. All rights reserved.